News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Protalex, Inc. (PRTX) Announces Dosing of First Patient in a Phase 1b Study of PRTX-100 in Patients With Active Rheumatoid Arthritis



8/20/2010 9:28:05 AM

SUMMIT, N.J., Aug. 20, 2010 (GLOBE NEWSWIRE) -- Protalex, Inc. (OTCBB:PRTX), a clinical stage biopharmaceutical company engaged in developing a class of biopharmaceutical drugs for treating autoimmune and inflammatory diseases, today announced the dosing of the first patient in a multicenter Phase 1b clinical study of PRTX-100 in adult patients with active Rheumatoid Arthritis (RA). The study is being conducted in South Africa.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES